Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 5, 2014, Pages

  Wei, Congwen ^a   Cao, Yuan ^b,c   Yang, Xiaoli ^a,d   Zheng, Zirui ^a   Guan, Kai ^a   Wang, Qiang ^b   Tai, Yanhong ^c   Zhang, Yanhong ^a   Ma, Shengli ^a   Cao, Ye ^a   Ge, Xiaoxing ^a   Xu, Changzhi ^a   Li, Jia ^a   Yan, Hui ^e   Ling, Youguo ^a   Song, Ting ^a   Zhu, Lin ^f   Zhang, Buchang ^f   Xu, Quanbin ^a   Hu, Chengjin ^c   Bian, Xiu Wu ^b   He, Xiang ^a,g   Zhong, Hui ^a   more..

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c JINAN MILITARY GENERAL HOSPITAL   (China)

^d Third Hospital of the General Brigade of Armed Police   (China)

^e BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^f ANHUI UNIVERSITY   (China)

^g BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; I KAPPA B KINASE EPSILON; IKK RELATED SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE; SERINE; SMALL INTERFERING RNA; TAMOXIFEN; TANK BINDING KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURVIVAL; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNITY, INNATE; KAPLAN-MEIER ESTIMATE; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; TAMOXIFEN; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 84893517865     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1316255111     Document Type: Article

References (46)

1. Fitzgerald KA, et al. (2003) IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4(5):491-496.
2. McWhirter SM, et al. (2004) IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci USA 101 (1):233-238.
3. Ishii KJ, et al. (2008) TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451(7179):725-729.
4. Xie X, et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA 108(16):6474-6479.
5. Chien Y, et al. (2006) RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127(1):157-170.
6. Guo JP, Coppola D, Cheng JQ (2011) IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 286(43):37389-37398.
7. Guo JP, et al. (2010) IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem 285(6):3676-3684.
8. Qin B, Cheng K (2010) Silencing of the IKKe gene by siRNA inhibits invasiveness and growth of breast cancer cells. Breast Cancer Res 12(5):R74.
9. Boehm JS, et al. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129(6):1065-1079.
10. Korherr C, et al. (2006) Identification of proangiogenic genes and pathways by highthroughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 103(11):4240-4245.
11. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474-1481.
12. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am J Clin Pathol 123(1):21-27.
13. Osborne CK, Schiff R, Fuqua SA, Shou J (2001) Estrogen receptor: Current understanding of its activation and modulation. Clin Cancer Res 7(12, Suppl)4338s-4342s, discussion 4411s-4412s.
14. Jordan VC, Gapstur S, Morrow M (2001) Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 93(19):1449-1457.
15. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11(4):643-658.
16. Shou J, et al. (2004) Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12): 926-935.
17. Clarke R, et al. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22(47):7316-7339.
18. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631-643.
19. Kato S, et al. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270(5241):1491-1494.
20. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS (1994) Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269(6):4458-4466.
21. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA (2006) Kinasespecific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20(12):3120-3132.
22. Murphy LC, Niu Y, Snell L, Watson P (2004) Phospho-serine-118 estrogen receptoralpha expression is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 10(17):5902-5906.
23. Murphy LC, Seekallu SV, Watson PH (2011) Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer 18(1):R1-R14.
24. Clark K, Plater L, Peggie M, Cohen P (2009) Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: A distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 284(21):14136-14146.
25. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
26. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2):101-112.
27. Jordan VC, O'Malley BW (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25(36):5815-5824.
28. Michalides R, et al. (2004) Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5(6): 597-605.
29. Williams CC, et al. (2009) Identification of four novel phosphorylation sites in estrogen receptor alpha: Impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem 10:36.
30. Le Romancer M, et al. (2011) Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr Rev 32(5):597-622.
31. Arnold SF, Vorojeikina DP, Notides AC (1995) Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J Biol Chem 270(50):30205-30212.
32. Britton DJ, et al. (2008) A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells. J Am Soc Mass Spectrom 19(5):729-740.
33. Chen D, Pace PE, Coombes RC, Ali S (1999) Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 19(2): 1002-1015.
34. Lee H, BaiW(2002) Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 22(16):5835-5845.
35. Jiang J, et al. (2007) Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res 13(19):5769-5776.
36. Kok M, et al. (2011) PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 125(1):1-12.
37. Holm C, et al. (2009) Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 217(3):372-379.
38. Bostner J, Skoog L, Fornander T, Nordenskjöld B, Stal O (2010) Estrogen receptoralpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 16(5): 1624-1633.
39. Ehrhardt C, et al. (2004) Rac1 and PAK1 are upstream of IKK-epsilon and TBK-1 in the viral activation of interferon regulatory factor-3. FEBS Lett 567(2-3):230-238.
40. Vendramini-Costa DB, Carvalho JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18(26):3831-3852.
41. Karin M, Greten FR (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749-759.
42. Hiscott J (2007) Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response. Cytokine Growth Factor Rev 18(5-6):483-490.
43. Robertson JF (1996) Oestrogen receptor: A stable phenotype in breast cancer. Br J Cancer 73(1):5-12.
44. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC).
45. US Office of Science and Technology Policy (1985) Laboratory animal welfare: U.S. government principles for the utilization and care of vertebrate animals used in testing, research, and training. Fed Regist 50(97):20864-20865.
46. He X, et al. (2010) c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation. Oncogene 29(15):2238-2251.